HomeComparePXSTF vs ABBV

PXSTF vs ABBV: Dividend Comparison 2026

PXSTF yields 2000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PXSTF wins by $13.31M in total portfolio value
10 years
PXSTF
PXSTF
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13.41M
Annual income
$131,835.96
Full PXSTF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PXSTF vs ABBV

📍 PXSTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPXSTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PXSTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PXSTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PXSTF
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$112,060.57/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PXSTF beats the other by $91,004.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PXSTF + ABBV for your $10,000?

PXSTF: 50%ABBV: 50%
100% ABBV50/50100% PXSTF
Portfolio after 10yr
$6.76M
Annual income
$78,303.86/yr
Blended yield
1.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PXSTF
No analyst data
Altman Z
1.2
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PXSTF buys
0
ABBV buys
0
No recent congressional trades found for PXSTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPXSTFABBV
Forward yield2000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$13.41M$102.3K
Annual income after 10y$131,835.96$24,771.77
Total dividends collected$9.45M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PXSTF vs ABBV ($10,000, DRIP)

YearPXSTF PortfolioPXSTF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$110,700$100,000.00$11,550$430.00+$99.2KPXSTF
2$635,739$517,289.72$13,472$627.96+$622.3KPXSTF
3$2,068,437$1,388,197.05$15,906$926.08+$2.05MPXSTF
4$4,323,805$2,110,576.40$19,071$1,382.55+$4.30MPXSTF
5$6,688,102$2,061,631.10$23,302$2,095.81+$6.66MPXSTF
6$8,646,433$1,490,163.82$29,150$3,237.93+$8.62MPXSTF
7$10,151,915$900,231.77$37,536$5,121.41+$10.11MPXSTF
8$11,356,463$493,914.25$50,079$8,338.38+$11.31MPXSTF
9$12,409,602$258,186.13$69,753$14,065.80+$12.34MPXSTF
10$13,410,110$131,835.96$102,337$24,771.77+$13.31MPXSTF

PXSTF vs ABBV: Complete Analysis 2026

PXSTFStock

Phoenix Media Investment (Holdings) Limited, an investment holding company, provides satellite television broadcasting services in the People's Republic of China and internationally. The company operates through five segments: Television Broadcasting, Internet Media, Outdoor Media, Real Estate, and Other Activities. The Television Broadcasting segment engages in broadcasting television programs and commercials; and provision of promotion activities through the operation of Phoenix Chinese and Phoenix InfoNews channels, as well as Phoenix Movies, Phoenix North America Chinese, Phoenix Chinese News and Entertainment, Phoenix Hong Kong, and other channels. The Internet Media segment offers website portal and value-added telecommunication services. The Outdoor Media segment provides outdoor advertising services. The Real Estate segment is involved in the property development and investment activities. The Other Activities segment offers program production and ancillary services, merchandising services, magazine publication and distribution, and other related services. It also provides radio broadcasting; research and development; cultural development; software and games development; trademark and property holding; hotel management; publishing and distributing periodicals; technical and financial consulting; aircraft chartering; exhibition; education technology; programme production; real estate brokerage; mobile value-add; capital market; and management and related services. The company was founded in 1996 and is headquartered in Tai Po, Hong Kong.

Full PXSTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PXSTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PXSTF vs SCHDPXSTF vs JEPIPXSTF vs OPXSTF vs KOPXSTF vs MAINPXSTF vs JNJPXSTF vs MRKPXSTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.